MedTrace Logo

Post Approval Study of the Commercially Available U-Motion II+ Acetabular System and UTF Reduced Stem

NCT02761499 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-06-05

No results posted yet for this study

Summary

This is a prospective, single arm, multi-center, post-approval study designed to evaluate the short and long term clinical performance and safety in subjects receiving primary total hip arthroplasty (THA) with the U-Motion II+ Acetabular System and UTF Reduced Stem.

Conditions

Interventions

DEVICE

U-Motion II+ Acetabular System

U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem

Sponsors & Collaborators

  • United Orthopedic Corporation

    lead INDUSTRY

Principal Investigators

  • Edwin Su, MD · HSS

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2023-08-31
Completion
2025-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02761499 on ClinicalTrials.gov